• News
  • SAN DIEGO
  • Health

Genalyte wins grant for diabetes work

Related Special Reports

San Diego-based Genalyte Inc. won a Small Business Innovation Research (SBIR) grant to develop multiplexed diagnostic assays for the early detection and monitoring of type 1 diabetes.

The $500,000 grant is from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health.

Genalyte's novel multiplexing technology simultaneously screens for the detection of multiple autoantibodies and other proteins using a one-step, 15-minute process.

Genalyte's Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.

"The unique capabilities of our Maverick multiplexed detection platform have the potential to provide researchers and clinicians with the tools to detect and track this process from a very early stage, when therapeutic intervention to interrupt the process could be feasible," said Martin Gleeson, Ph.D., chief scientific officer of Genalyte.

The SBIR-funded program initially will create a basic multiplexed assay to detect autoimmune response for known targets for type 1 diabetes.

It will then expand the approach to profile autoantibody response by multiple criteria, which is expected to enhance the ability of researchers and clinicians to detect and monitor the development of the disease.

Once the autoantibody panels have been developed and tested, they will be refined and validated using samples from patients with type 1 diabetes.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!